Current and future etiologic therapy of bacterial pneumonia. 1. Antibiotic therapy for community-acquired pneumonia

Main Article Content

А.Е. Abaturov
Т.А. Kryuchko

Abstract

The progressive increase in the prevalence of respiratory infections caused by multiresistant pathogenic agents is a serious problem requiring strict indications and development of algorithms for prescribing antibacterial drugs for pneumonia treatment. Amoxicillin is a drug of choice for the treatment of community-acquired pneumonia with a mild and uncomplicated course in children. The indications for prescribing macrolides are the patient’s allergy to β-lactam antibiotics or suspect mycoplasmal or chlamydial etiology of pneumonia. The choice of amoxicillin/clavulanate or cephalosporins for oral administration is proved by the laboratory data or a clinical suspicion of pneumonia caused by pathogens producing β-lactamases. The treatment strategy with the use of non-antibiotic agents for antibiotic-associated diseases therapy is being actively developed currently.

Article Details

How to Cite
Abaturov А., and Kryuchko Т. “Current and Future Etiologic Therapy of Bacterial Pneumonia. 1. Antibiotic Therapy for Community-Acquired Pneumonia”. CHILD`S HEALTH, vol. 12, no. 3, June 2017, pp. 382-9, doi:10.22141/2224-0551.12.3.2017.104231.
Section
To Help the Pediatrician

References

Allen RC, Popat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol. 2014 Apr;12(4):300-8. doi: 10.1038/nrmicro3232.

Aminov R. History of antimicrobial drug discovery: Major classes and health impact. Biochem Pharmacol. 2017 Jun 5. pii: S0006-2952(16)30331-8. doi: 10.1016/j.bcp.2016.10.001.

Arshad H, Fasanya A, Cheema T, Singh AC. Acute Pneumonia. Crit Care Nurs Q. 2016 Apr-Jun;39(2):148-60. doi: 10.1097/CNQ.0000000000000108.

Bradley JS, Byington CL, Shah SS, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011 Oct;53(7):617-30. doi: 10.1093/cid/cir625.

Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011 Oct;53(7):e25-76. doi: 10.1093/cid/cir531.

Breuer O, Blich O, Cohen-Cymberknoh M, et al. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy. Pediatr Pulmonol. 2015 May;50(5):495-502. doi: 10.1002/ppul.23159.

Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J. 2016 Jul;35(7):752-9. doi: 10.1097/INF.0000000000001159.

Cilloniz C, Martin-Loeches I, Garcia-Vidal C, et al. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. Int J Mol Sci. 2016 Dec 16;17(12). pii: E2120. doi: 10.3390/ijms17122120.

Esposito S, Cohen R, Domingo JD, et al Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J. 2012 Jun;31(6):e78-85. doi: 10.1097/INF.0b013e318255dc5b.

Fernández-Mormontoy J, Estremadoyro-Gallardo A, Vargas OF. Mortality predictive scores for community-acquired pneumonia in children. Pediatr Pulmonol. 2017 Apr 11. doi: 10.1002/ppul.23706.

Haq IJ, Battersby AC, Eastham K, McKean M. Community acquired pneumonia in children. BMJ. 2017 Mar 2;356:j686. doi: 10.1136/bmj.j686.

Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011 Oct;66 Suppl 2:ii1-23. doi: 10.1136/thoraxjnl-2011-200598.

Harrison CJ, Woods C, Stout G, et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother. 2009;63:511-9. doi: 10.1093/jac/dkn538.

Hazir T, Fox LM, Nisar YB, et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency tria. Lancet. 2008 Jan 5;371(9606):49-56. doi: 10.1016/S0140-6736(08)60071-9.

Hüseyin K, Akyol S, Parkan ÕM, et al. Molecular characterization and antibiotic susceptibility of Haemophilus influenzae clinical isolates. Infez. Med. 2017 Mar 1;25(1):27-32. PMID: 28353452.

Kealey C, Creaven CA, Murphy CD, Brady CB. New approaches to antibiotic discovery. Biotechnol Lett. 2017 Jun;39(6). doi: 10.1007/s10529-017-2311-8.

Laopaiboon M., Panpanich R., Swa Mya K. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev. 2015 Mar 8;(3):CD001954. doi: 10.1002/14651858.CD001954.pub4.

Lassi ZS, Das JK, Haider SW, et al. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. Arch Dis Child. 2014 Jul;99(7):687-93. doi: 10.1136/archdischild-2013-304023.

Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis.. Lancet. 2015 Jan 31;385(9966):430-40. doi: 10.1016/S0140-6736(14)61698-6.

Lodha R, Randev S, Kabra SK. Oral Antibiotics for Community acquired Pneumonia with Chest indrawing in Children Aged Below Five Years: A Systematic Review. Indian Pediatr. 2016 Jun 8;53(6):489-95. PMID: 27376603.

Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect. 2015 Mar;70(3):213-22. doi: 10.1016/j.jinf.2014.10.004.

Nijnik A, Hancock R. Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerg Health Threats J. 2009;2:e1. doi: 10.3134/ehtj.09.001.

Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol. 2016 Jun 22;7:974. doi: 10.3389/fmicb.2016.00974.

Pelton SI, Jacobs MR, authors. Pneumococcal Infections. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 7th ed. Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, editors. Philadelphia: Saunders; 2014. pp. 1198-1245.

Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries. Geneva: World Health Organization; 2014. WHO Guidelines Approved by the Guidelines Review Committee.

Ribeiro CF, Ferrari GF, Fioretto JR. Antibiotic treatment schemes for very severe community-acquired pneumonia in children: a randomized clinical study. Rev Panam Salud Publica. 2011 Jun;29(6):444-50. PMID: 21829969.

Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis 2007 Mar;57(3 Suppl):5S–12S. doi: 10.1016/j.diagmicrobio.2006.12.014.

Vincent JL, Bassetti M, François B, et al. Advances in antibiotic therapy in the critically ill. Crit Care. 2016 May 17;20(1):133. doi: 10.1186/s13054-016-1285-6.

Xaba SN, Greeff O, Becker P. Determinants, outcomes and costs of ceftriaxone v. amoxicillin-clavulanate in the treatment of community-acquired pneumonia at Witbank Hospital. S Afr Med J. 2014 Mar;104(3):187-91. PMID: 24897821.

Most read articles by the same author(s)

1 2 3 > >>